Hefei Lifeon Pharmaceutical Co., Ltd. Class A

As of June 30, 2026, Hefei Lifeon Pharmaceutical Co., Ltd. Class A carries a market capitalization of 3.38B, placing it among publicly traded companies globally. Its enterprise value stands at 3.06B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Hefei Lifeon Pharmaceutical Co., Ltd. Class A's next confirmed earnings release is scheduled for October 30, 2026.

As of June 30, 2026, Hefei Lifeon Pharmaceutical Co., Ltd. Class A has 228.22M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Hefei Lifeon Pharmaceutical Co., Ltd. Class A maintains a current ratio of 2.44, meaning it holds 2.4x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Hefei Lifeon Pharmaceutical Co., Ltd. Class A recorded 14.88M in income tax expense.

As of the close on October 23, 2026, Hefei Lifeon Pharmaceutical Co., Ltd. Class A's stock has declined approximately 31.08% over the past 52 weeks. The 50-day moving average sits at 17.52, while the 200-day moving average is 18.85.

As of June 30, 2026, Hefei Lifeon Pharmaceutical Co., Ltd. Class A holds 552.46M in cash and equivalents against 91.88M in total debt, resulting in a net debt position of -138.77M. Total book value stands at 1.84B, with working capital of 730.06M providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Hefei Lifeon Pharmaceutical Co., Ltd. Class A paid dividends of 0.43 per share.

Hefei Lifeon Pharmaceutical Co., Ltd. Class A's most recent stock split took place on May 29, 2026 with a 5:6 split ratio.